Department of Clinical Laboratory Genetics

Genome Diagnostics & Cancer Cytogenetics

Malignant Hematology Testing



Eaton Wing 11-444, 200 Elizabeth Street

Toronto, Ontario M5G 2C4

Head: Tracy Stockley, PhD, FCCMG, FACMG

Phone: (416) 340-4800 x5739

Fax: (416) 340-3596 Cancer Cytogenetics Fax: (416) 340-4473 Genome Diagnostics

Email: Genome.diagnostics@uhn.ca

Hours of Operation (Mon-Fri) 8:30AM-4:30PM

CAP: 7175217 CLIA: 99D1106115 IQMH: 4204-site 0141

Patient Information or Hospital Stamp Here Last Name: First Name: Date of Birth (MM/DD/YYYY): Sex assigned at birth: Health Card #: Hospital #:

Toronto Western Princess Margaret

Instructions:

THIS REQ IS FOR MALIGNANT HEMATOLOGY TESTING ONLY - see link at bottom of page for SOLID TUMOUR Full Name of Referring Physician and HEREDITARY requisitions.

- 1.Complete all information as requested
- 2. Send requisition with specimen to address above

DO NOT COME TO TORONTO GENERAL FOR **BLOOD DRAW**

- 3. Keep specimen at room temperature unless
- 4.If shipping, send same day or next day delivery 5. Specimen labelling: Name, DOB, MRN#, Date

Taken

Information For Reporting:

Physician Billing # Hospital/Address:

Phone	

Fax:
Physician Signature:
Copy Report To:
sepy report res

Specimen	Requi	ireme	nts –	Genon	ne
Diagnostic	s:				

Peripheral blood

For leukemia/lymphoma - 20 mL in EDTA For circulating tumour (cell free DNA) - 18 ml in STRECK tubes For all other testing - 5ml in EDTA

Bone marrow aspirate

1-2 ml in EDTA

Extracted DNA or RNA (>1µ	ʒ) (please	circle n	ucleic ac	id)

Tissue Source _____ Concentration: Volume:

Extracted nucleic acid will only be accepted from an appropriately accredited laboratory (ex.IQMH or equivalent).

Specimen Requirements – Cytogenetics (Page 3):

☐Bone marrow aspirate >1.5 ml in sodium heparin

☐Peripheral blood 5-10 ml in sodium heparin

□Paraffin Embedded Tissue (FISH)

- -include circled H&E
- -2 x 4μm sections/probe on positively charged slides, air dried

□Cytology preparation (FISH)

- -Air-dried smear/touch prep (1-2 per test)
- -Cytospin slide (1-2 per test)

N.B. Currently, decalcified specimens cannot be reported clinically.



Department of Clinical Laboratory Genetics

Genome Diagnostics & Cancer Cytogenetics -

Malignant Hematology

Toronto General Hospital

Eaton Wing 11-444, 200 Elizabeth Street

Toronto, Ontario M5G 2C4

Head: Tracy Stockley, PhD, FCCMG, FACMG Phone: (416) 340-4800 x5739 FAX: (416) 340-4473

Email: Genome.diagnostics@uhn.ca

Hours of Operation (Mon-Fri) 8:30AM-4:30PM

CAP: 7175217 CLIA: 99D1106115 IQMH: 4204-site 0141

Patient Information or Hospital Stamp Here Last Name:
First Name:
Date of Birth (MM/DD/YYYY):
Sex:
Health Card #:
Hospital #:

Clinical Diagnosis/Reason for	
Referral: Diagnosis:	☐ Monitoring: (for follow-up samples) Treatment (specify type)
☐ Other:	Date of last treatment

Genome Diagnostics Tests - Hematological

Le	un	וסי	a.

- □ ^BCR::ABL1 t(9;22)
 - Please indicate if known CML or ALL
- □ ^ABL1 kinase domain mutation
 - Please indicate breakpoint if known p210 or p190
- RUNX1::RUNX1T1 (AML/ETO) t(8;21)
- ☐ CBFB::MYH11 Inv(16) or t(16;16)
- PML::RARA t(15;17)
- ☐ FLT3/NPM1 (newly diagnosed AML)
- ☐ FLT3 only (relapsed/refractory AML)
- NPM1 MRD (4bp insertion between nucleotide 863 and 864 only)
- ☐ CLL/SLL IGHV Somatic Hypermutation/TP53 (for patients requiring treatment only)

Malignant Hematology NGS panel:

Funded for AML, MPN, MDS, and MDS/MPN. Please provide supporting documentation for testing. If molecular profiling was previously performed at another institution, please provide molecular results.

☐ Comprehensive Sequencing (NGS), includes:

ASXL1 CUX1 BCOR DDX41 BCORL1 DNMT3A BRAF ETNK1 CALR ETV6 CBL EZH2 CEBPA FBXW7 CSF3R FLT3 CTNNA1 GATA2	GNAS IDH1 IDH2 IKZF1 IRF1 JAK1 JAK2 KIT KMT2A	KRAS MPL MYD88 NOTCH1 NPM1 NRAS PAX5 PHF6 PPM1D	PTPN11 RAD21 RUNX1 SETBP1 SF3B1 SH2B3 SRSF2 STAG2 TET2	TP53 U2AF1 WT1 ZRSR2
---	---	---	--	-------------------------------

Lymphoma: please attach corresponding pathology report

- ☐ ^B-cell Clonality
- ☐ ^T-cell Clonality
- □ ^MYD88
- ☐ ^Mantle cell (TP53 sequencing only)

Bone marrow/Stem cell transplant monitoring:

□ ^15 STRs and amelogenin XY loci

Please specify:

- Donor
- ☐ Recipient Pre-SCT
- ☐ Recipient Post-SCT (Split Chimerism)

Other:

- □^BRAF (p.V600E/K only) (please select: Hairy cell leukemia, Langerhans cell histiocytosis, Erdheim-Chester)
- □^KIT (Mastocytosis BM or involved tissue preferred)
- □^JAK2 (Exon 12 + Exon 14 p.V617F) / CALR (MPD)

Identity Testing (15 STRs and amelogenin XY loci):

^Specimen matching (Please provide control specimen, specimen in question and details)

Andicates a test that will be billed to the referring hospital, laboratory, physician or medical group.

Page 2/3 Version 8.3 July 2023



Department of Clinical Laboratory Genetics Genome Diagnostics & Cancer Cytogenetics -

Malignant Hematology Testing

Toronto General Hospital

Eaton Wing 11-444, 200 Elizabeth Street

Toronto, Ontario M5G 2C4

☐ Diagnosis:

Head: Tracy Stockley, PhD, FCCMG, FACMG

Phone: (416) 340-4800 x5739 FAX: (416) 340-3596

Email: cancercytogenetics@uhn.ca

Hours of Operation (Mon-Fri) 8:30AM-4:30PM

CAP: 7175217 CLIA: 99D1106115 IQMH: 4204-site 0141

Clinical Diagnosis/Reason for Referral:

	Patient Information or Hospital Stamp Here Last Name:
S	First Name:
	Date of Birth (MM/DD/YYYY):
	Sex:
	Health Card #:
	Hospital #:

A bone marrow report must accompany or be sent by fax/email for all bone marrow samples.

Cancer Cytogenetics – Malignant Hematology

☐ Monitoring:	All samples will be banked and testing delayed until this information is received.
G-Banded Karyotyping Bone Marrow or Peripheral Blood for Oncology (marro G-banded karyotype analysis.	ow: ≥1.5mL NaHep, blood: 5-10mL NaHep).
Peripheral blood for CONSTITUTIONAL ANALYSIS (5-10) G-banded karyotyping to confirm a constitutional abn	omL NaHep). ormality detected on bone marrow karyotype. We do not to rule out an abnormality detected by karyotype or OGM .
□ PDGFRA / PDGFRB / FGFR1 / PCM1 / JAK2 / ABL1 / E Acute Myeloid Leukemia (B/M) – Bone Marrow (PREF	ERRED) or Blood (>10% blasts) (NaHep or EDTA) E FOR AML, PLEASE INDICATE BLAST PERCENTAGE ASAP
Fluorescence in situ Hybridization (FISH)	
Chronic Myelogenous Leukemia (B/M) □ ^BCR::ABL1 (only for molecular negative)	FISH for Lymphoid Disorders (continued) Large B-Cell Lymphoma Panel (B/M/C/P) ^Reflex Panel (BCL2 and BCL6 only when MYC
FISH for Plasma Cell Neoplasms Plasma Cell Neoplasms with CD138 Cell Enrichment (Magnetic separation requires ≥ 1mL marrow aspirate If other tests are requested, e.g. karyotype, please submit an additional 1.5-2mL of aspirate in a separate tube.) (M) ^Multiple Myeloma Panel (or Amyloidosis)	MYC ONLY
- Widiciple Myeloma Panel (of Amyloidosis)	Anaplastic large cell lymphoma (B/M/P)
FISH for Lymphoid Disorders	□ ^ALK
Chronic Lymphocytic Leukemia (B/M) ^CLL FISH Panel (WBC > 5x10 ⁹ cells/mL)	MALT lymphoma (B/M/C/P) AMALT1
□ diagnostic	Mantle cell lymphoma (B/M/C/P)
□ follow up	□ ^CCND1/IGH t(11;14)(q13;q32)
Indicates FISH validation status by sample type: B = Blood, M	= Marrow, P = Paraffin (surgical or cytology slides), C = Cytospin

^ indicates a test that will be billed to the referring hospital, laboratory, physician or medical group.